Theranostic Study of PSMA-Targeted Radioligands Modified with Enhancer SNAC

Tao Zhang's dataset on figshare contains results from a preclinical study evaluating novel PSMA-targeted radioligands for prostate cancer theranostics. The data likely includes radiochemical purity (>98%), binding affinity (IC50 = 19.1 nM), and in vivo biodistribution results from PC-3 PIP tumor-bearing mice. The dataset was last updated on 2026-05-28.

Use Cases

• Compare the binding affinity of novel SNAC-conjugated ligands based on reported IC50 values.
• Evaluate radiochemical purity and hydrophilicity of modified radioligands for preclinical screening.
• Analyze tumor uptake and systemic retention from PET and biodistribution studies in mouse models.
• Assess therapeutic efficacy and safety profiles of novel radioligands compared to established agents like PSMA-617.

Strengths

• Reports specific quantitative results, including a high radiochemical purity (>98%) and a binding affinity IC50 of 19.1 nM.
• Includes comparative data from in vivo studies in PC-3 PIP tumor-bearing mice.
• Provides results for three distinct SNAC-modified ligands (PSA3-1, PDA3-1, PDB3-1) with different linkers.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (348.0 KB), indicating a limited scope of data.

Provenance

Source

Tao Zhang via figshare

Collection Method

Experimental study involving synthesis, radiolabeling, affinity assays, and preclinical animal models.

Freshness

Last updated 2026-05-28 08:05:43; freshness should be verified.